Scandion Oncology A/S (SCOL.ST)
SEK 0.08
(-6.78%)
SEK 0.08
(-6.78%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 34.56 Million DKK | -61.34% |
| 2022 | 89.4 Million DKK | -23.08% |
| 2021 | 116.21 Million DKK | -37.65% |
| 2020 | 186.4 Million DKK | 836.6% |
| 2019 | 19.9 Million DKK | 46.74% |
| 2018 | 13.56 Million DKK | 591.35% |
| 2017 | 1.96 Million DKK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 38.98 Million DKK | 46.36% |
| 2024 Q1 | 26.63 Million DKK | -22.93% |
| 2023 Q2 | 60.18 Million DKK | -18.53% |
| 2023 Q3 | 50.83 Million DKK | -15.54% |
| 2023 FY | 34.56 Million DKK | -61.34% |
| 2023 Q1 | 73.87 Million DKK | -17.37% |
| 2023 Q4 | 34.56 Million DKK | -32.01% |
| 2022 Q2 | 87.72 Million DKK | -13.36% |
| 2022 FY | 89.4 Million DKK | -23.08% |
| 2022 Q4 | 89.4 Million DKK | -16.03% |
| 2022 Q3 | 106.47 Million DKK | 21.37% |
| 2022 Q1 | 101.25 Million DKK | -12.87% |
| 2021 Q4 | 116.21 Million DKK | -10.29% |
| 2021 Q2 | 144.55 Million DKK | -6.06% |
| 2021 Q1 | 153.88 Million DKK | -17.45% |
| 2021 FY | 116.21 Million DKK | -37.65% |
| 2021 Q3 | 129.54 Million DKK | -10.38% |
| 2020 Q2 | 13.93 Million DKK | -14.62% |
| 2020 Q3 | 11.33 Million DKK | -18.64% |
| 2020 FY | 186.4 Million DKK | 836.6% |
| 2020 Q4 | 186.4 Million DKK | 1544.05% |
| 2020 Q1 | 16.32 Million DKK | -17.98% |
| 2019 Q3 | 23.15 Million DKK | 196.58% |
| 2019 Q2 | 7.8 Million DKK | -32.32% |
| 2019 Q1 | 11.53 Million DKK | -14.93% |
| 2019 Q4 | 19.9 Million DKK | -14.05% |
| 2019 FY | 19.9 Million DKK | 46.74% |
| 2018 Q2 | 1.31 Million DKK | 0.0% |
| 2018 Q3 | 1.77 Million DKK | 34.63% |
| 2018 Q4 | 13.56 Million DKK | 663.41% |
| 2018 FY | 13.56 Million DKK | 591.35% |
| 2017 Q4 | 1.96 Million DKK | 0.0% |
| 2017 FY | 1.96 Million DKK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Lipum AB (publ) | 12.11 Million SEK | -185.384% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 70.823% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -72.446% |
| BioArctic AB (publ) | 1.18 Billion SEK | 97.086% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 44.595% |
| Mendus AB (publ) | 755.95 Million SEK | 95.428% |
| Intervacc AB (publ) | 259.61 Million SEK | 86.688% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 17.634% |
| Active Biotech AB (publ) | 44 Million SEK | 21.455% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 87.602% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 44.394% |
| Aptahem AB (publ) | 63.02 Million SEK | 45.165% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 93.036% |
| Kancera AB (publ) | 65.64 Million SEK | 47.352% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 90.163% |
| Fluicell AB (publ) | 9.34 Million SEK | -270.021% |
| Saniona AB (publ) | 64.14 Million SEK | 46.12% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -2.851% |
| Biovica International AB (publ) | 131.4 Million SEK | 73.7% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 34.774% |
| AcouSort AB (publ) | 34.51 Million SEK | -0.136% |
| Xintela AB (publ) | 18.39 Million SEK | -87.877% |
| Ziccum AB (publ) | 14.97 Million SEK | -130.831% |
| Genovis AB (publ.) | 288.85 Million SEK | 88.036% |
| Abliva AB (publ) | 87.49 Million SEK | 60.502% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 95.454% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 97.254% |
| OncoZenge AB (publ) | 20.34 Million SEK | -69.912% |
| CombiGene AB (publ) | 120.61 Million SEK | 71.346% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.189% |
| Corline Biomedical AB | 100.1 Million SEK | 65.476% |
| Amniotics AB (publ) | 26.08 Million SEK | -32.485% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 80.488% |
| 2cureX AB (publ) | 16.62 Million SEK | -107.88% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -468.702% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.182% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 95.484% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -14.539% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 75.419% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -59.242% |
| I-Tech AB | 152.44 Million SEK | 77.329% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 96.605% |
| Cyxone AB (publ) | 43.65 Million SEK | 20.834% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 56.082% |
| Biosergen AB | 7.2 Million SEK | -379.933% |
| Cantargia AB (publ) | 223.71 Million SEK | 84.552% |
| NextCell Pharma AB | 81.28 Million SEK | 57.485% |
| Nanologica AB (publ) | 77.42 Million SEK | 55.366% |
| SynAct Pharma AB | 228.01 Million SEK | 84.843% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -29.134% |
| LIDDS AB (publ) | 17.65 Million SEK | -95.752% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 97.532% |
| Alzinova AB (publ) | 123.18 Million SEK | 71.946% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 85.502% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 59.449% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -308.752% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -132.43% |
| Simris Alg AB (publ) | 174.55 Million SEK | 80.201% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 84.077% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 94.712% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 60.309% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -21.229% |